SCHEDULE: Morgan Stanley Declines Stake in Tenax Therapeutics
Ownership Filing Amendment
Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed a Schedule 13G amendment indicating they no longer beneficially own more than five percent of Tenax Therapeutics, Inc. common stock.
Summary
- Morgan Stanley and Morgan Stanley Capital Services LLC have filed an amendment to their Schedule 13G filing.
- This amendment signifies that both entities have ceased to be beneficial owners of more than five percent of the common stock of Tenax Therapeutics, Inc.
- As of the filing date, Morgan Stanley beneficially owned 596,564 shares, representing 3.5% of the class.
- Morgan Stanley Capital Services LLC beneficially owned 583,297 shares, representing 3.4% of the class.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports a change in institutional ownership below a significant threshold, rather than providing operational or financial performance updates.
Negatives
- Morgan Stanley and its subsidiary have reduced their stake in Tenax Therapeutics below the 5% threshold, indicating a divestment or rebalancing of their holdings.
Future Outlook
The filing does not contain forward-looking statements or guidance regarding future share ownership by Morgan Stanley or its subsidiaries.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors who acquire beneficial ownership of more than 5% of a company's registered class of securities. An amendment, such as this one, often signifies a change in the investor's position, potentially due to market activity, portfolio adjustments, or strategic decisions.
Stakeholder Impact
- Shareholders of Tenax Therapeutics may note the reduction in holdings by a significant institutional investor, which could be interpreted in various ways depending on broader market sentiment and company performance.
Key Dates
| Date | Description |
|---|---|
| 03/31/2026 | Date of Event Which Requires Filing of this Statement |
| 04/08/2026 | Date of Signatures for Morgan Stanley and Morgan Stanley Capital Services LLC |
Keywords
Schedule 13G, Tenax Therapeutics, Morgan Stanley, Beneficial Ownership, Securities Filing, Amendment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.